ABVC Biopharma Overview
- Year Founded
-
1990
- Status
-
Public
- Employees
-
19
- Stock Symbol
-
ABVC
- Investments
-
6
- Share Price
-
$0.87
- (As of Friday Closing)
ABVC Biopharma General Information
Description
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
Contact Information
Website
abvcbiopharma.comCorporate Office
- 44370 Old Warm Springs Boulevard
- Fremont, CA 94538
- United States
Corporate Office
- 44370 Old Warm Springs Boulevard
- Fremont, CA 94538
- United States
ABVC Biopharma Stock Performance
As of 20-Nov-2026, ABVC Biopharma’s stock price is $0.87. Its current market cap is $23.4M with 27M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.87 | $0.88 | $0.71 - $2.87 | $23.4M | 27M | 81.8K | -$0.15 |
ABVC Biopharma Financials Summary
As of 30-Sep-2026, ABVC Biopharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 32,806 | 55,330 | 8,963 | 11,782 |
| Revenue | 0 | 0 | 510 | 152 |
| EBITDA | (6,343) | (7,599) | (4,430) | (6,516) |
| Net Income | (3,915) | (7,909) | (4,903) | (7,788) |
| Total Assets | 20,296 | 21,062 | 7,540 | 7,784 |
| Total Debt | 2,511 | 3,473 | 2,431 | 2,595 |
ABVC Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ABVC Biopharma Comparisons
Industry
Financing
Details
ABVC Biopharma Competitors (7)
One of ABVC Biopharma’s 7 competitors is Cidara Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cidara Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Nektar Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Bright Angel Therapeutics | Venture Capital-Backed | Toronto, Canada |
ABVC Biopharma Patents
ABVC Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2767935-A1 | Coated substrates and methods of preparing the same | Inactive | 31-Jul-2009 | ||
| EP-2459016-A2 | Coated substrates and methods of preparing the same | Inactive | 31-Jul-2009 | ||
| WO-2011014831-A2 | Coated substrates and methods of preparing the same | Inactive | 31-Jul-2009 | ||
| WO-2011014831-A3 | Coated substrates and methods of preparing the same | Inactive | 31-Jul-2009 | ||
| US-20080254303-A1 | Actinic radiation curable; solvent-free dispersion containing amorphous silica filler | Inactive | 10-Apr-2007 | C09D4/00 |
ABVC Biopharma Signals
ABVC Biopharma Investments & Acquisitions (6)
ABVC Biopharma’s most recent deal was a Corporate Asset Purchase with ABVC Biopharma (Land in Puli, Nantou County, Taiwan) for . The deal was made on 01-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ABVC Biopharma (Land in Puli, Nantou County, Taiwan) | 01-Mar-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Zhong Hui Lian He Ji Tuan (Certain Property and a Parcel of Land Chengdu, China) | 14-Aug-2023 | Secondary Transaction - Private | Buildings and Property | ||
| Biokey | 08-Feb-2019 | Merger/Acquisition | Biotechnology | ||
| Seene | 25-Sep-2014 | Merger/Acquisition | Accessories | ||
| OCIS | 26-Jul-2007 | Merger/Acquisition | Other Commercial Services |
ABVC Biopharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
ABVC Biopharma Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Biokey | Fremont, CA | 2000 | |
| AiBtl BioPharma | Fremont, CA |
ABVC Biopharma FAQs
-
When was ABVC Biopharma founded?
ABVC Biopharma was founded in 1990.
-
Where is ABVC Biopharma headquartered?
ABVC Biopharma is headquartered in Fremont, CA.
-
What is the size of ABVC Biopharma?
ABVC Biopharma has 19 total employees.
-
What industry is ABVC Biopharma in?
ABVC Biopharma’s primary industry is Drug Discovery.
-
Is ABVC Biopharma a private or public company?
ABVC Biopharma is a Public company.
-
What is ABVC Biopharma’s stock symbol?
The ticker symbol for ABVC Biopharma is ABVC.
-
What is the current stock price of ABVC Biopharma?
As of 20-Nov-2026 the stock price of ABVC Biopharma is $0.87.
-
What is the current market cap of ABVC Biopharma?
The current market capitalization of ABVC Biopharma is $23.4M.
-
Who are ABVC Biopharma’s competitors?
Cidara Therapeutics, Nektar Therapeutics, Genentech, Novartis, and Bright Angel Therapeutics are some of the 7 competitors of ABVC Biopharma.
-
What is ABVC Biopharma’s annual earnings per share (EPS)?
ABVC Biopharma’s EPS for 12 months was -$0.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process